{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T17:56:13Z","timestamp":1792518973503,"version":"4.5.0"},"reference-count":32,"publisher":"Portland Press Ltd.","issue":"1","license":[{"start":{"date-parts":[[2019,12,16]],"date-time":"2019-12-16T00:00:00Z","timestamp":1576454400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["portlandpress.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,1,31]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Although radioactive iodine (131I) treatment (RIT) is recommended as the preferred option for patients with Graves\u2019 disease (GD), the predictive factors for its clinical outcomes are still unclear. In the present study, we aim to investigate the factors influencing the success rate of RIT treatment on primary GD with a calculated dose approach. The thyroid function (hyperthyroidism, euthyroidism or hypothyroidism) was evaluated at least 1 year after RIT, and its relationship with presenting clinical characteristics and pre-RIT parameters was analyzed in 45 patients retrospectively. After RIT, the remission rate was 62.2%, including 13 euthyroidism cases (28.9%) and 15 hypothyroidism cases (33.3%). We found no significant association between the types of thyroid function and age, gender, the 3-h radioactive iodine uptake (RAIU) prior to RIT, or radioactive iodine (131I) dosage. However, a variable 24-h RAIU &amp;gt; 46.31% was found associated with the success rate of RIT. The present study implied that a calculated dose approach for GD is effective, but high failure rates are expected in patients presenting poor 24-h RAIU, particularly those with 24-h RAIU below 46.31%.<\/jats:p>","DOI":"10.1042\/bsr20191609","type":"journal-article","created":{"date-parts":[[2019,12,16]],"date-time":"2019-12-16T11:43:12Z","timestamp":1576496592000},"update-policy":"https:\/\/doi.org\/10.1042\/crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Predictive factors for the outcomes of Graves\u2019 disease patients with radioactive iodine (131I) treatment"],"prefix":"10.1042","volume":"40","author":[{"given":"Yu-Zhuo","family":"Xing","sequence":"first","affiliation":[{"name":"Department of Nuclear Medicine, The Second Affiliated Hospital, Harbin Medical University, Harbin 150081, Heilongjiang, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, The Second Affiliated Hospital, Harbin Medical University, Harbin 150081, Heilongjiang, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9051-064X","authenticated-orcid":false,"given":"Gang","family":"Jin","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, The Second Affiliated Hospital, Harbin Medical University, Harbin 150081, Heilongjiang, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"288","published-online":{"date-parts":[[2020,1,3]]},"reference":[{"key":"2021111619575110900_B1","doi-asserted-by":"publisher","first-page":"2544","DOI":"10.1001\/jama.2015.16535","article-title":"Management of Graves disease: a review","volume":"314","author":"Burch","year":"2015","journal-title":"JAMA"},{"key":"2021111619575110900_B2","first-page":"342","article-title":"The effect of salt iodization for 10 years on the prevalences of endemic goiter and hyperthyroidism","volume":"18","author":"Zhang","year":"2002","journal-title":"Chin J. Endocrinol. Metab."},{"key":"2021111619575110900_B3","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1007\/s40618-016-0505-x","article-title":"Management of hyperthyroidism due to Graves\u2019 disease: frequently asked questions and answers (if any)","volume":"39","author":"Bartalena","year":"2016","journal-title":"J. Endocrinol. Invest."},{"key":"2021111619575110900_B4","first-page":"511","article-title":"Comparison of curative effect of 131I and antithyroid drugs in Graves\u2019 disease: a meta analysis","volume":"43","author":"Yuan","year":"2017","journal-title":"Minerva Endocrinol."},{"key":"2021111619575110900_B5","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1089\/thy.1997.7.369","article-title":"Clinical features of patients with Graves\u2019 disease undergoing remission after antithyroid drug treatment","volume":"7","author":"Vitti","year":"1997","journal-title":"Thyroid"},{"key":"2021111619575110900_B6","first-page":"1073","article-title":"High dose of (131)I therapy for the treatment of hyperthyroidism caused by Graves\u2019 disease","volume":"87","author":"Alexander","year":"2002","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"2021111619575110900_B7","first-page":"1038","article-title":"Age and gender predict the outcome of treatment for Graves\u2019 hyperthyroidism","volume":"85","author":"Allahabadia","year":"2000","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"2021111619575110900_B8","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1210\/jc.2002-020805","article-title":"A randomized comparison of radioiodine doses in Graves\u2019 hyperthyroidism","volume":"88","author":"Leslie","year":"2003","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"2021111619575110900_B9","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1097\/RLU.0b013e31824851d1","article-title":"Predictive factors of failure in a fixed 15 mCi 131I-iodide therapy for Graves\u2019 disease","volume":"37","author":"Moura-Neto","year":"2012","journal-title":"Clin. Nucl. Med."},{"key":"2021111619575110900_B10","doi-asserted-by":"publisher","first-page":"3257","DOI":"10.1097\/RLU.0b013e31824851d1","article-title":"Changes in thyroid volume in response to radioactive iodine for Graves\u2019 hyperthyroidism correlated with activity of thyroid-stimulating antibody and treatment outcome","volume":"81","author":"Murakami","year":"1996","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"2021111619575110900_B11","doi-asserted-by":"publisher","first-page":"8479","DOI":"10.1186\/1757-1626-0002-0000008479","article-title":"Extremely high doses of radioiodine required for treatment of Graves\u2019 hyperthyroidism: a case report","volume":"2","author":"Neto","year":"2009","journal-title":"Cases J."},{"key":"2021111619575110900_B12","first-page":"1229","article-title":"Success rate of radioiodine therapy in Graves\u2019 disease: the influence of thyrostatic medication","volume":"84","author":"Sabri","year":"1999","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"2021111619575110900_B13","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1111\/j.1365-2362.2004.01349.x","article-title":"Radioiodine therapy in hyperthyroidism: inverse correlation of pretherapeutic iodine uptake level and post-therapeutic outcome","volume":"34","author":"Walter","year":"2004","journal-title":"Eur. J. Clin. Invest."},{"key":"2021111619575110900_B14","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1507\/endocrj.51.127","article-title":"Onset age is associated with outcome of radioiodine therapy in Graves\u2019 disease","volume":"51","author":"Yamashita","year":"2004","journal-title":"Endocr. J."},{"key":"2021111619575110900_B15","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1097\/01.mnm.0000183795.59097.42","article-title":"High pre-therapy [99mTc]pertechnetate thyroid uptake, thyroid size and thyrostatic drugs: predictive factors of failure in [131I]iodide therapy in Graves\u2019 disease","volume":"26","author":"Zantut-Wittmann","year":"2005","journal-title":"Nucl. Med. Commun."},{"key":"2021111619575110900_B16","first-page":"225","article-title":"Treatment of Graves\u2019 hyperthyroidism\u2013prognostic factors for outcome","volume":"28","author":"Alfadda","year":"2007","journal-title":"Saudi Med. J."},{"key":"2021111619575110900_B17","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1097\/MAJ.0000000000000288","article-title":"Predictive factors of outcomes in personalized radioactive iodine ((131)I) treatment for Graves\u2019 disease","volume":"348","author":"Liu","year":"2014","journal-title":"Am. J. Med. Sci."},{"key":"2021111619575110900_B18","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1097\/MNM.0000000000000152","article-title":"Response rate and factors affecting the outcome of a fixed dose of RAI-131 therapy in Graves\u2019 disease: a 10-year Egyptian experience","volume":"35","author":"El-Kareem","year":"2014","journal-title":"Nucl. Med. Commun."},{"key":"2021111619575110900_B19","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1097\/MNM.0000000000000152","article-title":"How should the dose of iodine-131 be determined in the treatment of Graves\u2019 hyperthyroidism?","volume":"88","author":"Kalinyak","year":"2003","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"2021111619575110900_B20","doi-asserted-by":"publisher","first-page":"958276","DOI":"10.1155\/2013\/958276","article-title":"Increasing the radioiodine dose does not improve cure rates in severe Graves\u2019 hyperthyroidism: a clinical trial with historical control","volume":"2013","author":"Dora","year":"2013","journal-title":"J. Thyroid. Res."},{"key":"2021111619575110900_B21","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/BF03347067","article-title":"A study of the efficacy of radioiodine therapy with individualized dosimetry in Graves\u2019 disease: need to retarget the radiation committed dose to the thyroid","volume":"34","author":"Schiavo","year":"2011","journal-title":"J. Endocrinol. Invest."},{"key":"2021111619575110900_B22","doi-asserted-by":"publisher","first-page":"13","DOI":"10.5603\/NMR.2015.0004","article-title":"A simple and accurate dosimetry protocol to estimate activity for hyperthyroidism treatment","volume":"18","author":"Skanjeti","year":"2015","journal-title":"Nucl. Med. Rev. Cent. East Eur."},{"key":"2021111619575110900_B23","doi-asserted-by":"crossref","DOI":"10.1007\/174_2012_674","volume-title":"Radioiodine Therapy of Hyperthyroidism in Graves\u2019 Disease","author":"Wong","year":"2012"},{"key":"2021111619575110900_B24","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1111\/j.1365-2265.1995.tb02039.x","article-title":"Is calculation of the dose in radioiodine therapy of hyperthyroidism worth while?","volume":"43","author":"Jarlov","year":"1995","journal-title":"Clin. Endocrinol. (Oxf.)"},{"key":"2021111619575110900_B25","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1055\/s-2008-1070506","article-title":"Volumetric analysis of thyroid lobes by real-time ultrasound (author\u2019s transl)","volume":"106","author":"Brunn","year":"1981","journal-title":"Dtsch. Med. Wochenschr."},{"key":"2021111619575110900_B26","first-page":"143","article-title":"Prediction of absorbed dose to normal organs in thyroid cancer patients treated with 131I by use of 124I PET and 3-dimensional internal dosimetry software","volume":"48","author":"Kolbert","year":"2007","journal-title":"J. Nucl. Med."},{"key":"2021111619575110900_B27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1046\/j.1365-2265.1997.d01-1737.x","article-title":"The development of transient hypothyroidism after iodine-131 treatment in hyperthyroid patients with Graves\u2019 disease: prevalence, mechanism and prognosis","volume":"46","author":"Aizawa","year":"1997","journal-title":"Clin. Endocrinol. (Oxf.)"},{"key":"2021111619575110900_B28","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s13139-013-0234-4","article-title":"Clinical significance of diffuse intrathoracic uptake on post-therapy I-131 scans in thyroid cancer patients","volume":"48","author":"Choi","year":"2014","journal-title":"Nucl. Med. Mol. Imaging."},{"key":"2021111619575110900_B29","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1097\/RLU.0b013e3182817c78","article-title":"High failure rates after (131)I therapy in Graves hyperthyroidism patients with large thyroid volumes, high iodine uptake, and high iodine turnover","volume":"38","author":"de Jong","year":"2013","journal-title":"Clin. Nucl. Med."},{"key":"2021111619575110900_B30","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1097\/RLU.0b013e3182817c78","article-title":"Re-induction of cell differentiation and (131)I uptake in dedifferentiated FTC-133 cell line by TSHR gene transfection","volume":"39","author":"Feng","year":"2012","journal-title":"Nucl. Med. Biol."},{"key":"2021111619575110900_B31","first-page":"969","article-title":"Comparative evaluation of two different dosage calculation protocols of iodine-131 in the treatment of hyperthyroidism","volume":"93","author":"Thientunyakit","year":"2010","journal-title":"J. Med. Assoc. Thai."},{"key":"2021111619575110900_B32","doi-asserted-by":"publisher","first-page":"4344","DOI":"10.1210\/jc.2006-0498","article-title":"Autoimmune thyroiditis and exposure to iodine 131 in the Ukrainian cohort study of thyroid cancer and other thyroid diseases after the Chernobyl accident: results from the first screening cycle (1998-2000)","volume":"91","author":"Tronko","year":"2006","journal-title":"J. Clin. Endocrinol. Metab."}],"container-title":["Bioscience Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/portlandpress.com\/bioscirep\/article-pdf\/doi\/10.1042\/BSR20191609\/865125\/bsr-2019-1609.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/portlandpress.com\/bioscirep\/article-pdf\/doi\/10.1042\/BSR20191609\/865125\/bsr-2019-1609.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,16]],"date-time":"2021-11-16T20:38:31Z","timestamp":1637095111000},"score":1,"resource":{"primary":{"URL":"https:\/\/portlandpress.com\/bioscirep\/article\/40\/1\/BSR20191609\/221501\/Predictive-factors-for-the-outcomes-of-Graves"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1,31]]}},"URL":"https:\/\/doi.org\/10.1042\/bsr20191609","relation":{},"ISSN":["0144-8463","1573-4935"],"issn-type":[{"value":"0144-8463","type":"print"},{"value":"1573-4935","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,1]]},"published":{"date-parts":[[2020,1]]},"article-number":"BSR20191609"}}